Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen‐Independent Prostate Cancer
McDonald K. Horne(National Institutes of Health Clinical Center), William L. Dahut(National Cancer Institute), Howard L. Parnes(National Institutes of Health), James L. Gulley(National Cancer Institute), William D. Figg(National Cancer Institute), Phil M. Arlen(National Cancer Institute), Catherine Parker(National Cancer Institute), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics)
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
March 1, 2003
Cited by 40
Related Papers
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|973
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590